These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 24001596)

  • 1. Clinical course of intoxication with the new anticonvulsant drug perampanel.
    Hoppner AC; Fauser S; Kerling F
    Epileptic Disord; 2013 Sep; 15(3):362-4. PubMed ID: 24001596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures.
    Gidal BE; Ferry J; Majid O; Hussein Z
    Epilepsia; 2013 Aug; 54(8):1490-7. PubMed ID: 23772853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of perampanel in children and adults with various epilepsy syndromes: A single-center postmarketing study.
    Singh K; Shah YD; Luciano D; Friedman D; Devinsky O; Kothare SV
    Epilepsy Behav; 2016 Aug; 61():41-45. PubMed ID: 27300147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies.
    Steinhoff BJ; Ben-Menachem E; Ryvlin P; Shorvon S; Kramer L; Satlin A; Squillacote D; Yang H; Zhu J; Laurenza A
    Epilepsia; 2013 Aug; 54(8):1481-9. PubMed ID: 23663001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307.
    Krauss GL; Perucca E; Ben-Menachem E; Kwan P; Shih JJ; Squillacote D; Yang H; Gee M; Zhu J; Laurenza A
    Epilepsia; 2013 Jan; 54(1):126-34. PubMed ID: 22905878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305.
    French JA; Krauss GL; Steinhoff BJ; Squillacote D; Yang H; Kumar D; Laurenza A
    Epilepsia; 2013 Jan; 54(1):117-25. PubMed ID: 22905857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The practical impact of altered dosing on perampanel plasma concentrations: pharmacokinetic modeling from clinical studies.
    Gidal BE; Majid O; Ferry J; Hussein Z; Yang H; Zhu J; Fain R; Laurenza A
    Epilepsy Behav; 2014 Jun; 35():6-12. PubMed ID: 24785428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absence of Liver Toxicity in Perampanel-Treated Subjects: Pooled results from partial seizure phase III perampanel clinical studies.
    Laurenza A; Yang H; Williams B; Zhou S; Ferry J
    Epilepsy Res; 2015 Jul; 113():76-85. PubMed ID: 25986193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerability and safety of perampanel: two randomized dose-escalation studies.
    Krauss GL; Bar M; Biton V; Klapper JA; Rektor I; Vaiciene-Magistris N; Squillacote D; Kumar D
    Acta Neurol Scand; 2012 Jan; 125(1):8-15. PubMed ID: 21883097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perampanel in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus.
    Strzelczyk A; Willems LM; Willig S; Rosenow F; Bauer S
    Expert Rev Clin Pharmacol; 2015; 8(6):733-40. PubMed ID: 26436331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perampanel for epilepsy with partial-onset seizures: a pharmacokinetic and pharmacodynamic evaluation.
    Schulze-Bonhage A
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1329-37. PubMed ID: 26111428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perampanel, a novel, non-competitive, selective AMPA receptor antagonist as adjunctive therapy for treatment-resistant partial-onset seizures.
    Rektor I
    Expert Opin Pharmacother; 2013 Feb; 14(2):225-35. PubMed ID: 23259931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perampanel: a novel antiepileptic for the adjunctive treatment of refractory partial onset seizures.
    Owen RT
    Drugs Today (Barc); 2013 Jan; 49(1):23-31. PubMed ID: 23362493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perampanel: expanding therapeutic options for patients with medically refractory secondary generalized convulsive seizures.
    Ko D; Ramsay RE
    Acta Neurol Scand Suppl; 2013; (197):36-43. PubMed ID: 23480155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel treatment options for epilepsy: focus on perampanel.
    Franco V; Crema F; Iudice A; Zaccara G; Grillo E
    Pharmacol Res; 2013 Apr; 70(1):35-40. PubMed ID: 23287426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AMPA receptor inhibitors for the treatment of epilepsy: the role of perampanel.
    Zaccara G; Giovannelli F; Cincotta M; Iudice A
    Expert Rev Neurother; 2013 Jun; 13(6):647-55. PubMed ID: 23739002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perampanel for the treatment of primary generalized tonic-clonic seizures in idiopathic generalized epilepsy.
    Rohracher A; Brigo F; Höfler J; Kalss G; Neuray C; Dobesberger J; Kuchukhidze G; Leitinger M; Trinka E
    Expert Opin Pharmacother; 2016 Jul; 17(10):1403-11. PubMed ID: 27267634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New antiepileptic drugs: focus on ezogabine, clobazam, and perampanel.
    Rudzinski LA; Vélez-Ruiz NJ; Gedzelman ER; Mauricio EA; Shih JJ; Karakis I
    J Investig Med; 2016 Aug; 64(6):1087-101. PubMed ID: 27252470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Possible effect of perampanel on focal status epilepticus after generalized tonic-clonic status epilepticus.
    Rösche J; Kampf C; Benecke R
    Acta Neurol Belg; 2014 Sep; 114(3):243-4. PubMed ID: 23801431
    [No Abstract]   [Full Text] [Related]  

  • 20. Perampanel-associated self-harm ideation after dosage increase.
    Kheloufi F; Default A; Perrouty B; Blin O; Micallef J
    Eur J Clin Pharmacol; 2018 Feb; 74(2):243-244. PubMed ID: 29128971
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.